The Hidden Operational Implications of MFN Drug Pricing

The Most Favored Nation (MFN) drug pricing policy is gaining momentum in the United States. While the policy’s breadth of implementation is still unclear, pharmaceutical manufacturers must be ready for the full range of potential market disruptions.

All 17 pharmaceutical manufacturers named by the Trump administration have made individual deals to offer some prescriptions at MFN prices. However, the exact terms of each agreement are confidential, making it difficult to understand the agreements’ impact on affordability and industry operations.

The MFN initiative aims to align U.S. drug prices with those of other countries. Members of Congress are pushing to codify MFN, but recent attempts fell short of the necessary votes. Additional attempts are likely because drug affordability is still a political priority.

The policy presents a delicate revenue game for drug manufacturers. According to the 2026 Model N State of Revenue Report, 39% of surveyed life sciences companies think MFN will have a negative impact on their revenue.

Based on what we do know, this policy is likely to cause more operational issues for manufacturers than tangible cost reductions for patients.

Behind the scenes of a pricing change

Any regulation that impacts drug pricing — whether MFN-related or not — sets off a cascade of administrative tasks. Teams have to update sales agreements, recalculate rebates, file additional reports and validate compliance. Pricing (domestic and global) and commercial strategy, contracts, finance, compliance and IT all need to implement these changes correctly. Delays or mistakes will lead to incorrect rebates, reporting errors, pricing conflicts and potential regulatory violations.

Then the manufacturer must assess downstream effects of the change across other channels, such as Medicaid best price, 340B exposure and commercial agreements. These evaluations require significant time and resources.

Adding international pricing to the mix adds even more administrative work. Historically, US and Ex-US operations functioned separately, but now US teams need visibility into global pricing, product volumes and launch strategies because decisions made in comparable global markets influence U.S. pricing and obligations.

The long-term impact of MFN

How disruptive MFN pricing becomes largely depends on how deeply it penetrates U.S. drug pricing. At the low end, MFN pricing is limited to the cash price option for uninsured or underinsured patients, and to the US Medicaid in the context of the GENEROUS program, operationalized as a guaranteed net unit price (GNUP). This would be minimally disruptive; Medicaid often already pays below MFN, and cash-paying patients are unlikely to materially shift the payer mix outside select therapeutic areas like weight loss and fertility.

At the other extreme, MFN clauses spread into Medicare and commercial contracts. That would push larger volumes to internationally benchmarked prices, creating major disruption. In the US, prices and manufacturer revenues could fall, constraining R&D investment. Abroad, launch prices could rise, and some markets might lose access altogether. The risk of eroding U.S. revenue could be too great to justify discounting based on foreign prices for a particular drug.

GlobalData’s Price Intelligence analysis found a 35% decrease in new pharmaceutical launches across Europe following MFN’s introduction. The organization said the drop is not exclusively caused by the policy, but it could be an early signal of future impacts.

Operational considerations for manufacturers

Data and automation will be essential for effective MFN management. Manufacturers must integrate their domestic and international systems to create a reliable data foundation for price comparisons and calculations.

A centralized repository enables teams to automatically identify and adjust contracts, rebate terms, payer agreements and government program obligations affected by MFN-related price changes across all channels. Manually executing these tasks creates too many delays and a significant margin for error.

With comprehensive data, manufacturers can use AI and analytics to evaluate go-to-market strategies in light of MFN. Teams can model launch sequencing, compare the revenue impact of different country-by-country pricing decisions and identify where a lower international price could create downstream consequences in the US. This insight will help drug companies balance global pricing pressures with maintaining profitability and access in domestic and international markets.

Real price relief requires more than MFN regulations

While we wait to see how MFN plays out, it’s unlikely to provide any short-term cost relief for patients. Prescription prices are determined by insurance design, with most people paying a flat fee or coinsurance at the pharmacy counter. Reductions in prices for payers won’t change those amounts.

Real progress on affordability will come from reshaping the entire drug pricing process, not adding another compliance requirement. Bringing more visibility into negotiated net prices for all payers is the first step. Until this happens, policies like MFN will create more operational complexity without any meaningful relief for patients.